Breast cancer experts convened during an OncLive Scientific Interchange and Workshop to discuss the evolving use of oral SERDs in ER-positive breast cancer.
Early-Stage HR+/HER2– Breast Cancer: Expert Perspectives on Evolving Approaches to Optimize Adjuvant Therapy
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5